Glatiramer acetate for immune recovery in people with HIV
Part of Immune system & allergy, Infections clinical trials.
This trial tests a medicine called glatiramer acetate (often used for multiple sclerosis) to see if it can help improve the immune system (CD4 cells) in people with HIV who have low CD4 counts despite successful viral suppression. It involves injecting the medicine under the skin three times a week for the study period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (but not older than 65).
- You have HIV-1 and are on antiretroviral therapy (ART).
- Your viral load has been undetectable (below 50 copies/mL) for more than 3 years.
- Your CD4 count is below 500 and your CD4/CD8 ratio is below 0.5, indicating poor immune recovery.
- You are not pregnant or planning to become pregnant during the study.
- You do not have active hepatitis B or C, or a history of certain cancers or blood disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a steroid can prevent severe immune overreactions in people starting HIV treatment who have had an AIDS-related infection. It aims to reduce complications and improve outcomes.
This study tests new treatments to help people with HIV who have low CD4 counts despite antiretroviral therapy. It aims to improve immune function and reduce the risk of infections.
This study looks at whether certain genetic changes in the HIV virus (called drug resistance mutations) affect how well your immune system recovers after you start HIV treatment. It could help doctors understand why some people on HIV therapy have better immune recovery than others.
This study tests two drugs, baricitinib and sirolimus, alone or together, to see if they can help control HIV after you stop your usual HIV medications for a short time. The goal is to see if these drugs can keep the virus from rebounding.
This study looks at how certain immune cells (NK cells) behave in people who have been on HIV treatment for a long time. It aims to understand why some people's immune systems respond differently, which could help improve future treatments.
This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.